Latest Medicare price drug negotiations includes Ozempic, Wegovy
Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.
Ozempic and Wegovy make the list of the next 15 drugs in Medicare negotiations: HHS
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer treatment Calquence, GSK’s chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta, and AbbVie’s antipsychotic medication Vraylar.
Medicare to Negotiate Lower Prices for Ozempic and 14 Other Drugs
Changes may be on the horizon regarding the cost of diabetes and weight loss drug titans like Ozempic and Wegovy. The Biden administration has announced the next round of prescription drugs selected for Medicare price negotiations.
Wegovy and Ozempic top list of 15 drugs up for next price negotiations
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of federal price negotiations, which are scheduled to begin this year, with resulting bargained prices going into effect in 2027.
Government picks 15 more prescription drugs for Medicare price negotiation
The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), has selected 15 additional drugs for pr
Ozempic/Wegovy and 14 Other Drugs Selected for Medicare Price Negotiation
The blockbuster diabetes and weight-loss drug semaglutide (Ozempic, Rybelsus, Wegovy) along with therapies for asthma, cancers, and various other conditions were among the 15 drugs the Biden administration selected for the next round of Medicare price negotiation.
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce prescription drug costs.
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Second Round of Medicare Drug Price Controls Perpetuates Flawed, Harmful Policy
The Centers for Medicare and Medicaid Services' (CMS) announcement of 15 new drugs to be subject to price controls under the Inflation Reduction Act (IRA) represents the continuation of a flawed federal policy that has failed to achieve its stated goals and is causing significant health and economic harm.
Biden Adds Ozempic to Medicare Price Renegotiation Talks
Biden's administration announced weight loss drugs Ozempic and Wegovy will be included on Medicare's list of medications subject to direct price negotiations.
HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...
Becker's Hospital Review3d
Trump's plans for HHS: 13 knowns
1. Mr. Trump announced in November 2024 that Robert F. Kennedy Jr., son of former Attorney General Robert F. Kennedy and nephew to President John F. Kennedy, is his pick for HHS Secretary. Mr. Kennedy ...